Abstract
Accurate prediction of outcome in advanced non-small-cell lung cancer (NSCLC) remains challenging. Even within the same stage and treatment group, survival and response to treatment vary. We set out to determine the predictive value of inflammatory markers C-reactive protein (CRP) and white blood cells (WBCS) in patients with advanced NSCLC. Patients were assigned a prognostic index (PI): 0 for crp 10 mg/L or less and WBCS 11x10⁹/L or less, 1 if one of the two markers was elevated, and 2 if both markers were elevated. We then used chest computed tomography (CT) imaging to evaluate response after 2 cycles of chemotherapy treatment. Of 134 patients, 46 had a PI of 0; 60, a PI of 1; and 28, a PI of 2. Disease progressed in 41 patients. Progression was significantly more frequent among patients with a PI of 2 (p = 0.008). Median survival was 20.0 months for the PI 0 group, 10.4 months for the PI 1 group, and 7.9 months for the PI 2 group (p < 0.001). The PI was the only significant prognostic factor for survival even after adjustment for performance status, smoking, and weight loss (hazard ratio: 1.57; 95% confidence interval: 1.2 to 2.14; p = 0.004). Inflammatory state correlates significantly with both chemotherapy response and survival in stage IV NSCLC. The PI may provide additional guidance for therapeutic decision-making.
Highlights
Patients with nsclc have heterogeneous tumour and host biology that leads to wide predictive and prognostic variance
The pi was the only significant prognostic factor for survival even after adjustment for performance status, smoking, and weight loss
The crp induced by a cytokine consortium in which interleukin-6 is the dominant partner was shown to be an important adverse survival determinant—independent of stage and performance status—in advanced cancer, including non-small-cell lung cancer 10,14,15
Summary
Accurate prediction of outcome in advanced nonsmall-cell lung cancer (nsclc) remains challenging. We set out to determine the predictive value of inflammatory markers C-reactive protein (crp) and white blood cells (wbcs) in patients with advanced nsclc
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have